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420Objective: The aim of the study was to establish clinical event rates for the On-X bileaflet mechanical heart
valve (On-X Life Technologies Inc, Austin, Tex) using an audit of data from the 3 centers within Europe
with the longest history of implanting.
Methods: All patients receiving the On-X valve between March 1, 1998, and June 30, 2009, at 3 European cen-
ters were studied. Data were collected using questionnaire and telephone surveys augmented by outpatient visits
and examination of clinical records.
Results: There were 691 patients, with a mean age of 60.3 years, who received 761 valves in total: 407 mitral
valve replacements, 214 aortic valve replacements, and 70 aorticþmitral valve replacements (dual valve re-
placement). Total follow-up was 3595 patient-years, with a mean of 5.2 years (range, 0–12.6 years). Early
(30 days) mortality was 5.4% (mitral valve replacement), 0.9% (aortic valve replacement), and 4.3%
(dual valve replacement). Linearized late (>30 days) mortality expressed per patient-year was 3.6% (mitral
valve replacement), 2.2% (aortic valve replacement), and 4.1% (dual valve replacement), of which valve-
related mortality was 0.5% (mitral valve replacement), 0.2% (aortic valve replacement), and 1.8% (dual valve
replacement). Late linearized thromboembolism rates were 1.0% (mitral valve replacement), 0.6% (aortic valve
replacement), 1.8% (dual valve replacement). Bleeding rates were 1.0% (mitral valve replacement), 0.4% (aor-
tic valve replacement), and 0.9% (dual valve replacement). Thrombosis rates were 0.1% (mitral valve replace-
ment), 0% (aortic valve replacement), and 0.3% (dual valve replacement). Reoperation rates were 0.6% (mitral
valve replacement), 0.2% (aortic valve replacement), and 1.2% (dual valve replacement).
Conclusions: The On-X valve has low adverse clinical event rates in longer-term follow-up (mean 5.2 years and
maximum 12.6 years). (J Thorac Cardiovasc Surg 2013;145:420-4)The On-X bileaflet mechanical valve (On-X Life Technolo-
gies Inc, Austin, Tex) uses pure pyrolytic carbon and has
a flared inlet designed to reduce inlet turbulence and an
elongated orifice to organize flow and reduce exit losses.
The valve has relatively thin leaflets that can align with
flow to reduce obstruction. In the aortic position, valves
25 mm and smaller in size are implanted with the sewing
cuff supra-annularly and the housing inside the annulus.
The valve was first implanted in September 1996 and be-
came commercially available in Europe in 1998. It is known
to have good short- and mid-term hemodynamic function1-3
and clinical results.4-7 However, there is little longer-term
information.e Guy’s and St Thomas Hospitals,a London, England; Hospital Clınico,b
rsity of Barcelona, Spain; and Onassis Cardiac Surgery Center,c Athens,
e.
: On-X Life Technologies funded the salary of the research staff at all centers
e time required to collect the audit data.
res: Authors have nothing to disclose with regard to commercial support.
d for publication Aug 6, 2011; revisions received Nov 19, 2011; accepted for
ation Dec 14, 2011; available ahead of print Feb 20, 2012.
for reprints: John B. Chambers, MD, FRCP, FACC, Cardiothoracic Centre, St
as’ Hospital, London SE1 7EH, England (E-mail: john.chambers@gstt.nhs.
23/$36.00
ht  2013 by The American Association for Thoracic Surgery
016/j.jtcvs.2011.12.059
The Journal of Thoracic and Cardiovascular SurgThe aim of the study was to establish adverse clinical
event rates for the On-X valve using an audit of data from
3 of the earliest implanting centers within Europe.
MATERIALS AND METHODS
Patients
The audit was conducted in 2010 for consecutive patients receiving
On-X valve implantation between March 1, 1998, and June 30, 2009, at
3 centers: Hospital Clinico, University of Barcelona, Spain; Onassis Car-
diac Surgery Center in Athens, Greece; and Guy’s and St Thomas’ Hospital
Trust in London, United Kingdom. Includedwere patients with supplemen-
tary procedures, including coronary bypass grafting and mitral repair.
Excluded were patients implanted with a second valve other than an On-
X and those, because of small numbers, who received tricuspid valves
alone or together with other valves. The On-X valve was used interchange-
ably with other designs, predominantly those from St Jude Medical Inc
(St Paul,Minn) and Carbomedics (Sorin Spa,Milano, Italy), with no formal
inclusion or exclusion criteria. Approval from the relevant local boards was
obtained where required.
Management
Cardioplegic arrest and moderate cooling were used in all cases. The
technique of implantation differed between the sites: inverting sutures
and pledgets (Barcelona and Athens), and inverting sutures and no pledgets
for the aortic position and everting for the mitral position (London). Target
international normalized ratio (INR) was 2 to 3 in aortic valve replacement
(AVR) and 2.5 to 3.5 in mitral valve replacement (MVR) including dual
valve replacement (DVR). Patients with coexistent coronary bypassery c February 2013
TABLE 1. Patient data at implantation with mean (standard
deviation) for age and number (percentage) for other measures
AVR
n ¼ 214
MVR
n ¼ 407
DVR
n ¼ 70
Age mean (SD), y 59.7 (9.6) 60.6 (13.1) 60.2 (13.7)
Gender (M:F) 158:56 203:204 42:28
Preoperative lesion N (%)
Stenosis 126 (44) 94 (21)
Regurgitation 91 (32) 299 (67)
Mixed 61 (22) 70 (16)
NYHA N (%)
I 39 (18) 12 (3) 4 (6)
II 79 (37) 66 (16) 9 (13)
III 71 (33) 203 (50) 38 (54)
IV 18 (8) 116 (29) 16 (23)
Previous surgery N (%) 21 (10) 116 (28) 18 (26)
Concomitant procedures N (%) 64 (30) 130 (32) 11 (16)
Rhythm N (%)
Sinus 178 (83) 184 (45) 28 (40)
Atrial fibrillation 24 (11) 198 (49) 38 (54)
Paced 11 (5) 25 (6) 3 (4)
SD, Standard deviation.
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
DVR ¼ dual valve replacement
INR ¼ international normalized ratio
MVR ¼ mitral valve replacement
NYHA ¼ New York Heart Association
TIA ¼ transient ischemic attack
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patients were monitored in a clinic, and few performed home INR control.
Follow-up was according to local practice at the implanting center, refer-
ring hospital, or family physician. All centers followed a common protocol
using questionnaire and telephone follow-up. Preoperative and operative
data were gathered from hospital records, and follow-up was augmented
with clinical records to confirm adverse events and cause of death. Adverse
events were defined by the Society of Thoracic Surgeons/American
Association for Thoracic Surgery/European Association for Cardiothoracic
Surgery definitions,8 and other cardiovascular complications not listed in
the definitions were recorded.
Statistics
Early complication rates at 30 days or less were calculated as percent-
ages. Late rates were expressed as linearized rates per patient-year after 30
days. Descriptive statistics were computed using Microsoft Excel 2007
(Microsoft Corp, Redmond, Wash), and comparisons and life tables were
calculated using MedCalc for Windows (Mariakerke, Belgium).RESULTS
Patients
A total of 722 patients (16%) with On-X valves were
identified from the total of 4556 mechanical valves im-
planted between 1998 and 2009. There were 8 tricuspid
valve replacements with or without another valve and 23 pa-
tients with double valves, including one of a differing de-
sign that was therefore excluded from the analysis. There
remained 691 patients, of whom 407 received MVR alone,
214 received AVR alone, and 70 received DVR, resulting in
761 valves in total. The most frequent valve sizes were aor-
tic size 23 mm and mitral size 27/29 mm.
Patient information at implantation is shown in Table 1.
AVR was predominantly for dominant stenosis (44%),
and MVR was predominantly for insufficiency (67%). As
expected, atrial fibrillation occurred more often in MVR
and DVR than AVR (P<.0001). Patients receiving AVR
had significantly lower New York Heart Association
(NYHA) classifications than those receiving MVR or
DVR (P<.001). Patients were in NYHA class III or IV pre-
operatively before AVR (42%), MVR (78%), and DVR
(77%). The cause of the aortic disease was calcific degen-
erative (43%), congenital (43%), rheumatic (5%), endo-
carditis (5%), redo-prosthetic valve (2%), and calcific of
uncertain cause (2%). The cause of the mitral disease was
degenerative (39%), rheumatic (40%), redo-prostheticThe Journal of Thoracic and Ca(10%), endocarditis (8%), calcified annulus (2%), and
congenital (1%).Clinical Event Rates
Operative (30 days) mortality was 5.4% for MVR,
0.9% for AVR, and 4.3% for DVR (Table 2). Linearized
late mortality (>30 days) was 3.6%/patient-year for
MVR, 2.2%/patient-year for AVR, and 4.1%/patient-year
for DVR. Figure 1 shows overall survival. Valve-related
mortality was 0.5%/patient-year for MVR, 0.2%/patient-
year for AVR, and 1.8%/patient-year for DVR. Survival
free of valve-related mortality is shown in Figure 2. Overall
survival, both early and late and survival free of valve-
related mortality, was better for AVR than MVR or DVR.
When patients with and without coronary bypass grafting
were compared, there were no significant differences in
mortality for AVR (P ¼ .095), MVR (P ¼ .236), or DVR
(P ¼ .907) groups.
There was a follow-up of 3595 patient-years. One patient
was lost to follow-up after leaving the hospital 2 weeks after
surgery. Overall, 53 patients (7.6%) were lost to follow-up.
The range in follow-up, excluding early mortality, was 0 to
12.6 years with a mean of 5.2 years and median of 5.5 years.
Clinical event rates are shown in Table 2. There were 20
reoperations that were for paravalvar regurgitation in 14 pa-
tients, endocarditis in 3 patients, and thrombosis in 2 pa-
tients. One patient had a tight subaortic ring of fibrous
tissue associated with extensive subendocardial fibrosis
not seen at the time of original mitral valve implantation.
There were no differences among AVR, MVR, and DVR
in rates of sudden death, thromboembolism (Figure 3),rdiovascular Surgery c Volume 145, Number 2 421
TABLE 2. Adverse events
Type
Rates
Aortic Mitral Double
Early
N (%)
Late
N (%/patient-y)
Early
N (%)
Late
N (%/patient-y)
Early
N (%)
Late
N (%/patient-y)
Death
Sudden 0 5 (0.4) 0 4 (0.2) 0 2 (0.6)
Cardiac 2 (0.9) 4 (0.3) 14 (3.4) 30 (1.6) 3 (4.3) 3 (0.9)
Noncardiac 0 19 (1.4) 8 (1.9) 24 (1.3) 0 3 (0.9)
Valve related 0 2 (0.2) 0 10 (0.5) 0 6 (1.8)
Total 2 (0.9) 30 (2.2) 22 (5.4) 68 (3.6) 3 (4.3) 14 (4.1)
Stroke 1 (0.5) 7 (0.5) 0 4 (0.2) 0 3 (0.9)
TIA 3 (1.4) 1 (0.1) 0 12 (0.6) 0 1 (0.3)
Peripheral 0 0 0 1 (0.1) 0 1 (0.3)
Thrombosis 0 0 0 2 (0.1) 0 1 (0.3)
Total TE 4 (1.9) 8 (0.6) 0 19 (1.0) 0 6 (1.8)
Major bleed 2 (0.9) 5 (0.4) 1 (0.2) 19 (1.0) 0 3 (0.9)
Endocarditis 1 (0.5) 3 (0.2) 0 5 (0.3) 0 3 (0.9)
PVL 0 4 (0.3) 1 (0.2) 12 (0.6) 0 4 (1.2)
Nonstructural other than PVL 0 0 0 1 (0.1)* 0 0
Reoperation 1 (0.5) 2 (0.2) 1 (0.2) 12 (0.6) 0 4 (1.2)
Arrhythmia 2 (0.9) 5 (0.4) 5 (1.2) 6 (0.3) 0 0
CHF 0 2 (0.2) 0 2 (0.1) 0 1 (0.3)
MI 0 0 2 (0.5) 0 0 0
TE, Thromboembolism; PVL, paravalvular leak; CHF, congestive heart failure; MI, myocardial infarction. *Subaortic ring of fibrous tissue.
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leak (Figure 5), or reoperation (Figure 6). AVR had greater
freedom from bleeding events and reoperation than MVR
and DVR, whereas all other life tables had no significant
differences. There were no differences in event rates be-
tween sites.DISCUSSION
This is the largest clinical report for the On-X valve in
terms of patient-years, with 691 patients followed for a me-
dian 5.5 years and up to 12.6 years. Previous studies of the
On-X valve have had a mean follow-up duration of 1.8 to 5FIGURE 1. Freedom from all-cause mortality.
422 The Journal of Thoracic and Cardiovascular Surgyears.7,9 Another study with a slightly larger population
size10 had a mean follow-up of only 2.8 years. We found
low early event rates and linearized mid- and long-term
event rates comparing favorably with other valve types.11,12
Transient ischemic attack (TIA) and thrombosis rates
were low. Valve thrombosis was not reported in AVR in
this or other series of On-X valves.3-6,10 This compares
favorably with other types of bileaflet valves in which
rates of 0% to 0.5% are reported.11 Thrombosis of the mi-
tral position was not observed in some series.4,5 Others
report a small number associated with subtherapeutic or,
usually, discontinued anticoagulation: 3 in our series, 3 in
the study by Tossios and colleagues,6 and 1 in the study
by Chan and colleagues.10 The rate of total thromboembo-
lism including stroke, TIA, peripheral embolism, and valve
thrombosis was low, with a linearized rate of 0.6% in the
aortic position, 1% in the mitral position, and 1.8% for
double valves. This compares with the reported thrombo-
embolism rate alone for other valves of 0.3% to 5% in
the aortic position and 1.3% to 5% in the mitral posi-
tion.10,11,12-18 However, comparison with different valve
designs is difficult because of population variation in the
non-prosthetic thrombotic risk factors, INR regimens,
care with which follow-up is made, and method of report-
ing. Background rates of TIA of 1.3% in patients aged 64
to 74 years are reported,19 which is similar to the rates in
this study and therefore consistent with a degree of under-
reporting related to the retrospective nature of our study.
However, the On-X valve may genuinely be of lowery c February 2013
FIGURE 4. Freedom from bleeding events.FIGURE 2. Freedom from valve-related mortality.
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as a result of its carbon technology20 and the design features
affecting transvalve flow patterns. Reported thromboembo-
lism is uncommon even in a population in whom 40% have
no or inadequate anticoagulation.9 Trials are in progress to
investigate the safety of low anticoagulation rates in the
On-X valve (PROACT; US registration NCT00291525).
No structural failures were found, and none have been re-
ported by other studies.3-6,10,11 This is similar to other types
of bileaflet mechanical valve other than the St Jude Medical
valve, the discontinued Hemex-Duromedics valve (origi-
nally Hemex Scientific Inc, Austin, Tex), and the Tekna-
Edwards valve (originally Baxter Healthcare Corp, Santa
Ana, Calif), for which a small number of leaflet escapes
have been reported.11-13 The endocarditis rate was low,
confirming previous reports.4,6 The incidence of reported
paraprosthetic regurgitation increased with time in all
positions but mainly in MVR and DVR after 2 years. This
is surprising. It is possible that washing jets were
misinterpreted, and there was no core laboratory toFIGURE 3. Freedom from thromboembolism.
The Journal of Thoracic and Caadjudicate on reports. However, most of the reoperations
were for valve dehiscence or endocarditis, and the
survival curves for paraprosthetic regurgitation (Figure 5)
and reoperation (Figure 6) match relatively well. It is there-
fore likely that the regurgitation was present immediately
after surgery, but that it was only detected when the patient
became unwell probably after a prolonged examination in-
cluding transesophageal echocardiography. The alternative
explanation that the regurgitation developed as a result of
cumulative stitch dehiscence is far less likely and was not
shown in other series.7 One patient required reoperation af-
ter MVR for a previously undescribed complication. There
was a tight subaortic ring of fibrous tissue associated with
extensive subendocardial fibrosis not seen at the time of
the original mitral valve implantation. The surgeon noted
that the housing of the mitral prosthesis was prominent
and speculated that it had abraded the outflow tract to cause
fibrosis.
The proportion of patients undergoing surgery who were
in NHYA class III or IV was 42% for AVR but more thanFIGURE 5. Freedom from paravalvar leaks.
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FIGURE 6. Freedom from reoperation.
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valves but slightly worse for mitral valves than in the Euro-
Heart survey,21 in which the proportions were 47% for aor-
tic stenosis, 58% for mitral regurgitation, and 63% for
mitral stenosis.Limitations
This was a retrospective audit, so the rates of minor clin-
ical events including minor thromboembolism and bleeds
are probably underreported. However, serious events such
as reoperation, valve thrombosis, or endocarditis would
unlikely have been missed. There was no systematic echo-
cardiography with core laboratory assessment of possible
paraprosthetic regurgitation, so the rates of paraprosthetic
regurgitation may be incorrect. Furthermore, 7.6% of pa-
tients were lost to follow-up, reflecting the mobility of our
populations, and this may have introduced inaccuracies.CONCLUSIONS
The On-X valve has low adverse clinical event rates in
longer-term follow-up (mean 5.2 years and maximum
12.6 years).424 The Journal of Thoracic and Cardiovascular SurgReferences
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